摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-nitrobenzyl)-5-(trifluoromethyl)pyridin-2(1H)-one | 923688-20-4

中文名称
——
中文别名
——
英文名称
1-(4-nitrobenzyl)-5-(trifluoromethyl)pyridin-2(1H)-one
英文别名
2(1H)-Pyridinone,1-[(4-nitrophenyl)methyl]-5-(trifluoromethyl)-;1-[(4-nitrophenyl)methyl]-5-(trifluoromethyl)pyridin-2-one
1-(4-nitrobenzyl)-5-(trifluoromethyl)pyridin-2(1H)-one化学式
CAS
923688-20-4
化学式
C13H9F3N2O3
mdl
——
分子量
298.221
InChiKey
FQHNXBPWRWVCFE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    432.0±45.0 °C(Predicted)
  • 密度:
    1.477±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    66.1
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    1-(4-nitrobenzyl)-5-(trifluoromethyl)pyridin-2(1H)-one盐酸铁粉 作用下, 以 乙醇 为溶剂, 反应 5.0h, 以97.8%的产率得到1-(4-aminobenzyl)-5-(trifluoromethyl)pyridin-2(1H)-one
    参考文献:
    名称:
    5-取代基-2(1 H)-吡啶酮衍生物作为抗纤维化剂的合成及构效关系
    摘要:
    吡啶酮化合物(例如吡非尼酮(PFD)和氟苯尼酮(AKF-PD))是多靶点抗纤维化药物。以PFD和AKF-PD为主导化合物,合成了两种新型的(5-取代基)-2(1 H)-吡啶酮化合物,以维持多靶点性质并克服快速代谢的缺点。这些衍生物通过以AKF-PD作为阳性对照的MTT分析显示出对NIH3T3细胞的良好增殖抑制活性。化合物5b具有很高的抗纤维化作用,IC 50为0.08 mmol / L,约为AKF-PD的34倍。还讨论了吡啶酮衍生物作为抗纤维化剂的SAR。
    DOI:
    10.1016/j.bmcl.2012.01.073
  • 作为产物:
    参考文献:
    名称:
    抗肾纤维化药物1-(取代苄基)-5-三氟甲基-2 (1H)-吡啶酮盐酸盐的合成方法
    摘要:
    本发明涉及一种抗肾纤维化药物1‑((4‑(4‑甲基哌嗪‑1‑基)丙基)氨基)苄基‑5‑三氟甲基‑2(1H)‑酮盐酸盐(ZHC‑116盐酸盐)的合成方法。本发明以2‑氯‑5‑三氟甲基吡啶(商业购得)为原料,经过9步合成步骤制备1‑((4‑(4‑甲基哌嗪‑1‑基)丙基)氨基)苄基‑5‑三氟甲基‑2(1H)‑酮。相比现有文献报道的方法,本发明的方法有效、实用,总合成收率有所提高,适合工业规模化生产。
    公开号:
    CN107652228B
点击查看最新优质反应信息

文献信息

  • PREPARATION OF 1-(SUBSTITUTED BENZYL)-5-TRIFLUOROMETHYL-2(1H)PYRIDONE COMPOUNDS AND SALTS THEREOF AND THEIR APPLICATIONS
    申请人:Hu Gaoyun
    公开号:US20120129859A1
    公开(公告)日:2012-05-24
    1-(substituted benzyl)-5-trifluoromethyl-2(1H)pyridone compounds and their pharmaceutical acceptable salts are disclosed. The preparation methods of the compounds and their salts and the use of the same for preparing the medicaments for treating fibrosis are also disclosed. New pyridine compounds and their salts are obtained from trifluoromethyl pyridone as starting material.
    揭示了1-(取代苄基)-5-三甲基-2(1H)吡啶酮化合物及其药用可接受盐。还公开了这些化合物及其盐的制备方法,以及用于制备治疗纤维化药物的用途。从三甲基吡啶酮作为起始物获得了新的吡啶化合物及其盐。
  • Synthesis and evaluation of new pirfenidone derivatives as anti-fibrosis agents
    作者:Chenxi Gu、Wei Li、Qing Ju、Han Yao、Lisheng Yang、Baijiao An、Wenhao Hu、Xingshu Li
    DOI:10.1039/d2ra00990k
    日期:——
    Two series of new pirfenidone derivatives, in which phenyl groups or benzyl groups are attached to the nitrogen atom of the pyridin-2(1H)-one moiety were synthesized and evaluated as anti-fibrosis agents. Among them, compound 5d, with a (S)-2-(dimethylamino) propanamido group in the R2 position (series 1) exhibited 10 times the anti-fibrosis activity (IC50: 0.245 mM) of pirfenidone (IC50: 2.75 mM)
    合成了两个系列的新吡非尼酮生物,其中苯基或苄基连接到 pyridin-2(1 H )-one 部分的氮原子上,并作为抗纤维化剂进行了评估。其中,在R 2位具有( S )-2-(二甲氨基)丙酰胺基的化合物5d (系列1)表现出10倍于吡非尼酮(IC 50 : 2.75 )的抗纤维化活性(IC 50 : 0.245 mM)毫米)。化合物9d (系列 2)对人成纤维细胞系 HFL1的 IC 50为 0.035 mM。还研究了最佳化合物抑制纤维化的机制。
  • 1-(SUBSTITUTED BENZYL)-5-TRIFLUOROMETHYL-2-(1H) PYRIDONE COMPOUNDS AND THEIR SALTS, THEIR PREPARATION METHODS AND USE THEREOF
    申请人:Central South University
    公开号:EP2474533A1
    公开(公告)日:2012-07-11
    1-(substituted benzyl)-5-trifluoromethyl-2(1H)pyridone compounds and their pharmaceutical acceptable salts are disclosed. The preparation methods of the compounds and their salts and the use of the same for preparing the medicaments for treating fibrosis are also disclosed. New pyridine compounds and their salts are obtained from trifluoromethyl pyridone as starting material.
    本发明公开了 1-(取代苄基)-5-三甲基-2(1H)吡啶酮化合物及其药用盐。此外,还公开了这些化合物及其盐的制备方法和用于制备治疗纤维化药物的用途。以三甲基吡啶酮为起始原料,可获得新的吡啶化合物及其盐。
  • Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy
    作者:Jun Chen、Zhangzhe Peng、Miaomiao Lu、Xuan Xiong、Zhuo Chen、Qianbin Li、Zeneng Cheng、Dejian Jiang、Lijian Tao、Gaoyun Hu
    DOI:10.1016/j.bmcl.2017.07.001
    日期:2018.1
    Oxidative stress, inflammation and fibrosis can cause irreversible damage on cell structure and function of kidney and are key pathological factors in Diabetic Nephropathy (DN). Therefore, multi-target agents are urgently need for the clinical treatment of DN. Using Pirfenidone as a lead compound and based on the previous research, two novel series (5-trifluoromethyl)-2(1H)-pyridone analogs were designed and synthesized. SAR of (5-trifluoromethyl)-2(1H)-pyridone derivatives containing nitrogen heterocyclic ring have been established for in vitro potency. In addition, compound 8, a novel agent that act on multiple targets of anti-DN with IC50 of 90 mu M in NIH3T3 cell lines, t(1/2) of 4.89 +/- 1.33 h in male rats and LD50 > 2000 mg/kg in mice, has been advanced to preclinical studies as an oral treatment for DN. (C) 2017 Elsevier Ltd. All rights reserved.
  • PREPARATION OF 1-(SUBSTITUTED BENZYL)-5-TRIFLUOROMETHYL-2-(1H)PYRIDONE COMPOUNDS AND SALTS THEREOF AND THEIR APPLICATIONS
    申请人:Central South University
    公开号:EP2474533B1
    公开(公告)日:2015-02-25
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫